Holen Sie sich die Stockscreener-App
61.31
1.53%
0.88
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$60.43
Offen:
$61.09
24-Stunden-Volumen:
7.53M
Relative Volume:
1.35
Marktkapitalisierung:
$24.05B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$571.50M
KGV:
42.92
EPS:
1.4285
Netto-Cashflow:
$570.80M
1W Leistung:
-11.38%
1M Leistung:
-8.49%
6M Leistung:
-24.83%
1J Leistung:
-11.97%
1-Tages-Spanne:
$58.88
$62.39
1-Wochen-Bereich:
$56.45
$69.17
52-Wochen-Spanne:
$56.45
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
61.34 | 23.57B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
125.30 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.42 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
361.67 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.05 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
84.08 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. - GlobeNewswire
Dexcom recalls G6 CGM app over software problem - MedTech Dive
DexCom (NASDAQ:DXCM) Given "Buy" Rating at Truist Financial - MarketBeat
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Is DexCom Inc. (DC4) stock cheap by valuation metricsMarket Risk Summary & Community Consensus Picks - newser.com
Can DexCom Inc. (DC4) stock hit consensus price targetsPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - Morningstar
Freestone Capital Holdings LLC Purchases 7,242 Shares of DexCom, Inc. $DXCM - MarketBeat
What MACD and RSI say about DexCom Inc.CEO Change & Smart Money Movement Alerts - newser.com
Has DexCom Inc. found a price floor2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Will breakout in DexCom Inc. lead to full recoveryQuarterly Market Review & Daily Profit Maximizing Trade Tips - newser.com
Will DexCom Inc. stock continue dividend increasesDollar Strength & Verified Chart Pattern Trade Signals - newser.com
Building trade automation scripts for DexCom Inc.July 2025 Breakouts & Weekly Setup with High ROI Potential - newser.com
DexCom, Inc. Experiences Valuation Adjustment Amidst Competitive Market Dynamics - Markets Mojo
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Securities Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Urged to Join Class Action Before December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit - PR Newswire
DexCom (DXCM): UBS Lowers Price Target to $95, Maintains 'Buy' R - GuruFocus
DexCom Faces Class Action Over Alleged Investor Deception - TipRanks
DXCM CLASS ACTION LAWSUIT: A Securities Fraud Class Action - GlobeNewswire
DexCom Stock Rises 3.7% on November 3, 2025 | DXCM NewsNews and Statistics - IndexBox
DexCom (DXCM) Stock Is Up, What You Need To Know - TradingView
DexCom Growth Outlook Likely Sustainable, UBS Says - MarketScreener
UBS Adjusts DexCom Price Target to $95 From $106, Maintains Buy Rating - MarketScreener
Truist Securities Reiterates Buy Rating on DexCom (DXCM) Despite - GuruFocus
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is DexCom Inc. (DC4) stock a top pick for value investorsPortfolio Value Summary & Verified Swing Trading Watchlist - newser.com
Can DexCom Inc. stock maintain operating marginsInsider Selling & Stock Portfolio Risk Management - newser.com
Will DexCom Inc. stock maintain momentum in 2025Inflation Watch & Weekly Momentum Stock Picks - newser.com
What does recent volatility data suggest for DexCom Inc.2025 Big Picture & Verified Entry Point Signals - newser.com
Is DexCom Inc. stock reversal real or fakeQuarterly Investment Review & Daily Stock Trend Reports - newser.com
FY2025 EPS Estimates for DexCom Increased by Leerink Partnrs - MarketBeat
What is William Blair's Forecast for DexCom FY2025 Earnings? - MarketBeat
Is DexCom Inc. stock attractive for passive investors2025 Momentum Check & Safe Capital Preservation Plans - newser.com
DexCom Inc. stock chart pattern explainedMarket Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Is DexCom Inc. (DC4) stock a buy for dividend portfoliosWall Street Watch & Daily Oversold Bounce Ideas - newser.com
Can DexCom Inc. stock sustain free cash flow growthEarnings Trend Report & Advanced Swing Trade Entry Alerts - newser.com
Will a bounce in DexCom Inc. offer an exitInflation Watch & Breakout Confirmation Alerts - newser.com
DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM)Contact Kessler Topaz Meltzer & Check, LLP - The Malaysian Reserve
Earnings Beat: DexCom, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Geneva Capital Management LLC Increases Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Acquired by Strs Ohio - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Q3 2025 Earnings Call Transcript - MSN
Is DexCom Inc. (DC4) stock supported by free cash flowQuarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
DexCom (NASDAQ:DXCM) Price Target Lowered to $75.00 at JPMorgan Chase & Co. - MarketBeat
What catalysts could drive DexCom Inc. stock higherWeekly Loss Report & Precise Swing Trade Entry Alerts - newser.com
DexCom Sees Unusually Large Options Volume (NASDAQ:DXCM) - MarketBeat
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):